De novo design of potent and selective interleukin mimetics
US-11655278-B2 · May 23, 2023 · US
De novo design of potent and selective interleukin mimetics
US12227553B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12227553-B2 |
| Application number | US-202318187639-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 21, 2023 |
| Priority date | Jun 25, 2018 |
| Publication date | Feb 18, 2025 |
| Grant date | Feb 18, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
De novo designed polypeptides that bind to IL-2 receptor βγ c heterodimer (IL-2Rβγ c ), IL-4 receptor αγ c heterodimer (IL-4Rαγ c ), or IL-13 receptor α subunit (IL-13Rα) are disclosed, as are methods for using and designing the polypeptides.
First claim
Opening claim text (preview).
We claim: 1. A recombinant host cell comprising an expression vector, wherein the expression vector comprises a nucleic acid operatively linked to a promoter, wherein the nucleic acid encodes a non-naturally occurring polypeptide wherein the polypeptide comprises an amino acid sequence at least 80% identical to the amino acid sequence set forth in SEQ ID NO: 181, wherein the polypeptide binds to IL-2 receptor βY c heterodimer (IL-2RβY c ). 2. The recombinant host cell of claim 1 , wherein the polypeptide comprises an amino acid sequence at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 181. 3. The recombinant host cell of claim 1 , wherein the polypeptide comprises an amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 181. 4. The recombinant host cell of claim 3 , wherein the amino acids at positions 10-17 relative to SEQ ID NO: 181 are identical to SEQ ID NO: 1; the amino acids at positions 37-44 relative to SEQ ID NO: 181 are identical to SEQ ID NO:2; and the amino acids at positions 91-99 relative to SEQ ID NO: 181 are identical to SEQ ID NO:3. 5. The recombinant host cell acid of claim 1 , wherein the polypeptide comprises an amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO: 181. 6. The recombinant host cell of claim 1 , wherein the polypeptide comprises an amino acid sequence at least 97% identical to the amino acid sequence set forth in SEQ ID NO: 181. 7. The recombinant host cell of claim 6 , wherein the amino acids at positions 10-17 relative to SEQ ID NO: 181 are identical to SEQ ID NO: 1; the amino acids at positions 37-44 relative to SEQ ID NO: 181 are identical to SEQ ID NO:2; and the amino acids at positions 91-99 relative to SEQ ID NO: 181 are identical to SEQ ID NO:3. 8. The recombinant host cell of claim 1 , wherein the polypeptide comprises an amino acid sequence at least 98% identical to the amino acid sequence set forth in SEQ ID NO: 181. 9. The recombinant host cell of claim 8 , wherein the amino acids at positions 10-17 relative to SEQ ID NO: 181 are identical to SEQ ID NO: 1; the amino acids at positions 37-44 relative to SEQ ID NO: 181 are identical to SEQ ID NO:2; and the amino acids at positions 91-99 relative to SEQ ID NO: 181 are identical to SEQ ID NO:3. 10. The recombinant host cell of claim 1 , wherein the polypeptide comprises an amino acid sequence that is 98% identical to the amino acid sequence set forth in SEQ ID NO: 181 and comprises a tyrosine at position 8 and a glutamic acid at position 33. 11. The recombinant host cell of claim 10 , wherein the polypeptide comprises an amino acid sequence that is 99% identical to the amino acid sequence set forth in SEQ ID NO: 181 and comprises a cysteine at position 62. 12. The recombinant host cell of claim 1 , wherein the amino acids at positions 10-17 relative to SEQ ID NO: 181 are identical to SEQ ID NO: 1; the amino acids at positions 37-44 relative to SEQ ID NO: 181 are identical to SEQ ID NO:2; and the amino acids at positions 91-99 relative to SEQ ID NO: 181 are identical to SEQ ID NO:3. 13. The recombinant host cell of claim 1 , wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 181.
Assignees
Inventors
Classifications
containing a fusion for binding to a cell surface receptor · CPC title
fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies · CPC title
Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title
IL-15 · CPC title
IL-4 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12227553B2 cover?
- De novo designed polypeptides that bind to IL-2 receptor βγ c heterodimer (IL-2Rβγ c ), IL-4 receptor αγ c heterodimer (IL-4Rαγ c ), or IL-13 receptor α subunit (IL-13Rα) are disclosed, as are methods for using and designing the polypeptides.
- Who is the assignee on this patent?
- Univ Washington, Univ Leland Stanford Junior
- What technology area does this patent fall under?
- Primary CPC classification C07K14/55. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).